David Malcom Rodman Sells 70,037 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 70,037 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $35.87, for a total transaction of $2,512,227.19. Following the completion of the sale, the insider owned 69,188 shares of the company’s stock, valued at approximately $2,481,773.56. The trade was a 50.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

David Malcom Rodman also recently made the following trade(s):

• On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.02, for a total transaction of $6,748,879.30.
• On Wednesday, October 15th, David Malcom Rodman sold 10,369 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $43.01, for a total transaction of $445,970.69.

Mineralys Therapeutics Stock Down 1.0%

Mineralys Therapeutics stock opened at $35.35 on Thursday. The firm has a fifty day simple moving average of $39.31 and a two-hundred day simple moving average of $30.24. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $47.65. The company has a market capitalization of $2.80 billion, a PE ratio of -11.98 and a beta of 0.49.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. As a group, equities analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Key Stories Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Analyst reaffirmation and price-target support — LifeSci Capital maintained a Buy rating and $54 price target for MLYS, citing lorundrostat’s broad efficacy and safety profile; several brokers have also raised targets recently, supporting upside expectations. Analyst Note
• Neutral Sentiment: Corporate update outlines upcoming clinical and regulatory milestones for lorundrostat and announces participation in investor events — this provides catalysts (data readouts/updates) but timing and results remain uncertain, so near-term impact is ambiguous. Corporate Update
• Negative Sentiment: Unusually large put-option buying — ~91,940 put contracts traded (a ~4,429% increase vs. average), signaling aggressive bearish or hedging activity that can pressure the stock and imply expectations of near-term downside or increased volatility.
• Negative Sentiment: Significant insider selling by David Malcom Rodman — multiple recent Form 4 filings show large sales (70,037 shares on Jan 2 and 192,715 shares on Jan 5, at roughly $35–$36 per share), representing a material reduction in his holdings. Large, concentrated insider sales can be interpreted negatively by the market even if proceeds are for personal reasons. Insider Trades

Analysts Set New Price Targets

MLYS has been the topic of several recent analyst reports. Wells Fargo & Company raised their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Stifel Nicolaus increased their price target on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, December 19th. HC Wainwright raised their price target on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.43.

Institutional Investors Weigh In On Mineralys Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Mineralys Therapeutics by 51.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Mineralys Therapeutics by 198.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock worth $40,000 after purchasing an additional 676 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Mineralys Therapeutics by 42.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after purchasing an additional 1,197 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Mineralys Therapeutics during the 2nd quarter valued at about $91,000. Finally, Russell Investments Group Ltd. increased its stake in Mineralys Therapeutics by 14,091.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after purchasing an additional 3,241 shares in the last quarter. 84.46% of the stock is owned by institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.